British pharmaceutical company GlaxoSmithKline (GSK) is investing a total of £275m at three of its UK-based manufacturing sites to increase production and support delivery of its latest respiratory and large molecule biological medicines.
A large part of these products manufactured at the three UK facilities will be exported to the international markets worldwide.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GSK chief executive officer Andrew Witty said: “Today’s announcement reflects further investment to support our pharmaceutical pipeline and meet growing demand for our innovative portfolio of newly launched products.
“It is testament to our skilled UK workforce and the country’s leading position in life sciences that we are making these investments in advanced manufacturing here.
“From their manufacture in the UK, many of these medicines will be sent to patients around the world.”
The company will invest £92m of the total £275m at the Barnard Castle site in County Durham, nearly £110m at Montrose in Angus, Scotland, and £74m at Ware in Hertfordshire.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe Barnard Castle site currently employs 1,100 people and is one of GSK’s biggest secondary manufacturing sites, supplying half a million packs of products across 140 global markets every day.
The £92m investment at the site will help fund the development of an aseptic sterile facility supporting the production of existing and new biopharmaceutical assets in the company’s pipeline.
The Montrose site manufactures active ingredients for respiratory, HIV and vaccine products and its £110m investment will be used to provide a new and modern facility for the production of respiratory active ingredients.
GSK’s investment at Ware will help the company expand its new Ellipta respiratory inhaler by developing additional manufacturing capacity at the site.
Ware in Hertfordshire currently employs 1,200 people and produces the latest and advanced respiratory products.
The new investments will help generate new employment opportunities at the three sites.
GSK owns nine manufacturing sites in the UK and employs a total of approximately 6,000 people.
